Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

  • Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices 
  • Standalone Sandoz committed to extend leadership in stable and growing market via purpose-driven strategy with focus on sustainable access 
  • Differentiating investment grade credit profile and six strategic levers to drive long-term value 
  • With over 77 years of experience, a solid foundation in the fields of generics and biosimilars, and more than 3000 employees in Slovenia, Lek is an integral part of the Sandoz group. 
4. 10. 2023

Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company. 

The new company is included in key SIX market indices and has an investment-grade credit rating that gives it a strong competitive position. It is well placed for continued profitable growth as a standalone global leader and European champion in generic and biosimilar medicines.

 “At Sandoz, our Purpose is unchanged: pioneering access for patients. It’s what we do best, have always done best, and will always do best: making affordable quality medicines available to more people, in more places, in more and novel ways.” Gilbert Ghostine, Chairman Sandoz

The opening bell-ringing ceremony at SIX headquarters this morning marks the successful completion of the 100% spin-off from former parent company Novartis and the start of trading in Sandoz Group AG shares. The shares are listed on the Swiss Performance Index (SPI®), the Swiss Leader Index (SLI®) and other relevant Swiss indices; Sandoz ADRs (American Depositary Receipts) will also be traded as of today on the US OTCQX®. 

Sandoz Board Chairman Gilbert Ghostine says: “Today marks the dawn of a new era for Sandoz as an independent company, but our Purpose is unchanged: pioneering access for patients. It’s what we do best, have always done best, and will always do best: making quality medicines available to more people, in more places, in more and novel ways.” 

The Sandoz Purpose and brand are deeply rooted in its scientific heritage and legacy of medical firsts since the foundation of chemical pioneer Kern & Sandoz back in 1886: from the development of Calcium Sandoz in 1929, via the world’s first oral penicillin in 1951, to the launch of the world’s first biosimilar in 2006. 

“As an independent company, Sandoz will be fully enabled to deliver on its purpose-driven strategy, which targets sustainable leadership in the growing and critical generics and biosimilars industry… we intend to make an even greater impact going forward.” Richard Seynor, CEO Sandoz

As outlined at the Sandoz Capital Markets Day in June, six strategic levers should drive long-term value: attractive market fundamentals, leadership and scale, multiple growth drivers, margin improvement, accelerated cash generation, and a compelling sustainability story. 

CEO Richard Saynor says: “As an independent company, Sandoz will be fully enabled to deliver on its purpose-driven strategy, which targets sustainable leadership in the growing and critical generics and biosimilars industry.” 

“We already actively pioneer access for patients by shaping the global healthcare environment. We strengthen healthcare systems worldwide by delivering over USD 17 billion in annual savings in Europe and the US alone and we reach some 500 million patients a year in over 100 countries. In doing so, we generate a total social impact estimated to be USD 180 billion annually. And we intend to make an even greater impact going forward.” 

Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost. Despite strong competitive pressures, the industry is set to grow steadily over the next decade, driven by underlying demand for these system-critical medicines. 

Robert Ljoljo, President of the Lek d.d. Board of Management and Sandoz Country President Slovenia, added: “As of today, Sandoz and Lek will be even more effective in addressing the needs of half a billion patients under our global wing, which includes Slovenia. Our brand refresh reflects our enduring commitment to healthcare innovation and our dedication to facing global healthcare challenges. Our culture is based on integrity and inclusion, which allow us to be our best selves. When we can stay true to our values, we contribute to the company’s growth and pioneer access for patients. With over 77 years of experience and a solid foundation in the fields of generics and biosimilars, Lek is a valued member of the Sandoz group. The scope of our operations and more than 3000 employees in Slovenia make us the largest company within the group, while two new investments place Slovenia on Sandoz’s map as an important European development and production center for biosimilars. The latter will play a vital part in delivering Sandoz’s mission. 

The Sandoz listing prospectus and related documents can be found here: www.sandoz.com/sandoz-spin. 


* * *

Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 500 million patients worldwide, generating substantial global healthcare savings and an even larger total social impact. Its leading portfolio of more than 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2022, Sandoz achieved sales of USD 9.1 billion and core EBITDA of USD 1.9 billion. 

* * *

This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. 

- end -
Global Media Relations contacts 
Investor Relations contacts 
Global.MediaRelations@sandoz.com 
Investor.Relations@sandoz.com 
Joerg E. Allgaeuer 
+49 171 838 4838 
Karen M. King 
+1 609 722 0982 
Chris Lewis 
+49 174 244 9501 
Laurent de Weck 
+41 79 795 7364 


Sandoz on social media 

LinkedIn 
X (Twitter) 
Instagram 
Facebook 
https://www.linkedin.com/company/sandoz 
https://twitter.com/sandoz_global 
https://www.instagram.com/sandozglobal 
https://www.facebook.com/sandozglobal 
CEO Richard Saynor on LinkedIn 
https://www.linkedin.com/in/richard-saynor